Jun

29

BANGALORE, June 29 (Reuters) - Teva Pharmaceutical Industries Ltd  said U.S. health regulators approved its partner Antares Pharma Inc’s needle-free injector device to administer the Israeli company’s human growth hormone.

 

                           “This is an important validation of the Teva partnership, which is  the primary driver of our valuation and excitement about Antares stock,” Ladenburg Thalmann analyst Matthew Kaplan said by phone.

Shares of Antares rose as much as 58 percent to a new year high of $1.14, before paring some gains to trade up at $1.02 in morning trade Monday on the American Stock Exchange.

Teva, the world’s largest generic drug maker, and Antares filed a supplemental new drug application last year to use the needle-free device to administer Tev-Tropin, a human growth hormone.

Human growth hormone is a protein, given by injection, that is commonly used to treat children with growth hormone deficiency.

                          

Take a look at the top selling HGH product by clicking here.

Read the entire HGH article here.


Comments

Name (required)

Email (required)

Website

Speak your mind

Comments are closed.